ZYME Zymeworks Inc.

47.42
+2.32  (+5%)
Previous Close 45.1
Open 45.37
Price To Book 6.03
Market Cap 1,867,747,615
Shares 39,309,157
Volume 485,706
Short Ratio 1.42
Av. Daily Volume 470,445
Stock charts supplied by TradingView

NewsSee all news

  1. Zymeworks Announces Pricing of $279.0 Million Public Offering

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics ("Zymeworks" or the "Company"), announced today the pricing of its previously-announced underwritten

  2. Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants

    Zymeworks Inc. (NYSE:ZYME) ("Zymeworks" or the "Company"), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, has today filed a preliminary prospectus supplement (the "Canadian

  3. Zymeworks Highlights 2019 Achievements and Announces Corporate Priorities

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2019 and updated its corporate priorities. Zymeworks also

  4. Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib)

    Potential for a Novel Chemotherapy-Free Treatment Option for People with Advanced HER2-positive, HR-positive Breast Cancer Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing

  5. Zymeworks to Present at the J.P. Morgan Healthcare Conference 2020

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will present a corporate overview and updated clinical

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 initial data released October 28, 2019. 5/9 partial responses.
ZW25
HER2-expressing Gastroesophageal Adenocarcinoma
Phase 1 data due 2020.
ZW49
HER2-Expressing Cancers
Phase 1 trial is ongoing.
ZW25 + chemo
HER2-expressing cancers
Phase 2 initiation announced January 12, 2020.
ZW25 and Ibrance
HER2-positive, HR-positive breast cancer

Latest News

  1. Zymeworks Announces Pricing of $279.0 Million Public Offering

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics ("Zymeworks" or the "Company"), announced today the pricing of its previously-announced underwritten

  2. Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants

    Zymeworks Inc. (NYSE:ZYME) ("Zymeworks" or the "Company"), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, has today filed a preliminary prospectus supplement (the "Canadian

  3. Zymeworks Highlights 2019 Achievements and Announces Corporate Priorities

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2019 and updated its corporate priorities. Zymeworks also

  4. Zymeworks Announces Agreement with Pfizer and Initiation of a New Phase 2 Trial Evaluating ZW25 in Combination with Ibrance® (palbociclib)

    Potential for a Novel Chemotherapy-Free Treatment Option for People with Advanced HER2-positive, HR-positive Breast Cancer Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing

  5. Zymeworks to Present at the J.P. Morgan Healthcare Conference 2020

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will present a corporate overview and updated clinical

  6. Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily pretreated patients with

  7. Zymeworks Announces Selection of ZW25 Abstract for Mini Oral Presentation at the European Society for Medical Oncology Asia (ESMO Asia) Congress

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the selection of an abstract highlighting updated single agent data from the Phase 1

  8. Zymeworks Files Automatic Shelf Registration Statement and Enters into At-The-Market Equity Offering Sales Agreement

    Zymeworks Inc. (NYSE:ZYME), a clinical‑stage biopharmaceutical company developing multifunctional therapeutics, announced today that it has filed an automatic shelf registration statement on Form S-3 (the "Registration

  9. Zymeworks Reports 2019 Third Quarter Financial Results

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2019. "We recently presented

  10. Zymeworks to Present at Stifel 2019 Healthcare Conference

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will present at the upcoming Stifel 2019 Healthcare Conference taking place

  11. Zymeworks Announces Phase 1 Data for ZW25 in Combination with Chemotherapy in Advanced Gastroesophageal Adenocarcinoma at AACR-NCI-EORTC International Conference

    ZW25 Plus Chemotherapy Shows Durable Activity in Patients with Heavily Pretreated Gastroesophageal Adenocarcinoma Data Continue to Support Ongoing Phase 2 Trial of ZW25 Plus Standard of Care Chemotherapy Therapy as

  12. Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at European Society for Medical Oncology (ESMO) Congress

    Single Agent Activity and Durable Disease Control Across Multiple Tumor Types Data Support the Initiation of a Registration-Enabling Phase 2 Trial Evaluating Single Agent ZW25 in Second-Line HER2-Expressing Biliary

  13. Zymeworks Announces New Chair of Board of Directors and Voluntary Delisting from the TSX

    Zymeworks Inc. (TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that Lota Zoth has been appointed as its Chair of the Board of Directors. Ms. Zoth succeeds

  14. Zymeworks to Participate in Upcoming Investor Conferences

    Zymeworks Inc. (TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will participate in three upcoming investor conferences. Wells Fargo